HIV, the virus that causes AIDS, has become one of the world's most devastating diseases since it was first recognized more than three decades ago.
Keep Reading →
August 23 - News
For a subgroup of the patients, the hazard ratio for overall survival in late-stage pancreatic cancer patients taking Incyte Corporation (NASDAQ:INCY)'s Jakafi and Roche's Xeloda...
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
August 22 - News
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur in the U.S.
Keep Reading →
August 21 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Ignore the bickering between shareholders of Sarepta Therapeutics Inc (NASDAQ:SRPT) and GlaxoSmithKline plc (ADR) (NYSE:GSK) /Prosensa for a moment, because these are exciting...
Keep Reading →
August 20 - News
If you've ever taken the time to really follow the biopharmaceutical sector, you know very well that failures are a dime a dozen, and success stories are few and far between.
Keep Reading →
August 19 - News
This could have been an enormously more difficult effort. I started out with the goal to identify the three best stocks in health care to buy and hold for years, even decades.
Keep Reading →
August 19 - News
At least the Food and Drug Administration is polite.
Keep Reading →
August 19 - News
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals, Inc.
Keep Reading →
August 5 - News
High yields aren't everything when you're searching for the perfect dividend stock.
Keep Reading →
August 1 - News
Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle...
Keep Reading →
August 1 - News
We are in the midst of the earnings season, my favorite time of the year.
Keep Reading →
July 29 - News
Gilead Sciences, Inc. (NASDAQ:GILD)' shares surged over 5% in after-hours trading on Thursday after the company announced its second-quarter earnings before giving up some of...
Keep Reading →
July 29 - News
It's easy to forget that AbbVie Inc (NYSE:ABBV) is technically only seven-months old.
Keep Reading →
July 29 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
July 26 - News
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Keep Reading →
July 25 - News
AbbVie Inc (NYSE:ABBV) will release its quarterly report on Friday, and with its stock having jumped considerably since it started trading as a separate entity, investors are ...
Keep Reading →
July 24 - News
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Keep Reading →
July 24 - News
For nearly two decades, investment pro Ken Fisher's stock picks have outperformed the overall market.
Keep Reading →
July 23 - News
Today, let's look at Fisher Asset Management, founded in 1979 by Ken Fisher.
Keep Reading →
July 23 - Hedge Funds
According to multiple reports , Harvard researchers Timothy Henrich and Daniel Kuritzkes have recently noted a surprising side-effect to cancer treatments performed on two separate...
Keep Reading →
July 22 - News
You may or may not have heard, but it's earnings season again.
Keep Reading →
July 22 - News
The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals.
Keep Reading →
July 22 - News
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News
The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the ...
Keep Reading →
July 11 - News
It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market.
Keep Reading →
July 10 - News
Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver.
Keep Reading →
July 10 - News
We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
Keep Reading →
July 8 - News
For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). After rejecting Amgen, Inc.
Keep Reading →
July 3 - News
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Keep Reading →
July 3 - News
AbbVie Inc (NYSE:ABBV) has risen more than 20% since it hit the market earlier this year. In fact, it has managed to beat the S&P 500 by nearly 10%.
Keep Reading →
July 1 - News
Stock price movements reflect investors' opinions about a company's worth; upward moves attracts investor interest because they indicates good performance.
Keep Reading →
July 1 - News
To prove my point, I looked at the multi-year chart and picked out some of the peaks.
Keep Reading →
July 1 - News
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) just can't catch a break.
Keep Reading →
June 28 - News
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Keep Reading →
June 27 - News
Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Keep Reading →
June 26 - News
Dividend stocks are hard to come by in the biotech space.
Keep Reading →
June 26 - News
Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry...
Keep Reading →
June 26 - News
For investors viewing AbbVie Inc (NYSE:ABBV) as a value play since its spin-off from Abbott Laboratories (NYSE:ABT), it is time to think again.
Keep Reading →
June 26 - News
Earnings Per Share (EPS) growth is one measure of a company's profitability. Since it is often the most commonly discussed performance metric, it tends to drive share prices.
Keep Reading →
June 25 - News
Hepatitis-C is a contagious virus that attacks the liver and can be found in acute or chronic forms.
Keep Reading →
June 24 - News
Gilead Sciences, Inc. (NASDAQ:GILD) has been one of the most prolific investments in the healthcare sector.
Keep Reading →
June 18 - News
Amgen, Inc. (NASDAQ:AMGN) is the world’s largest independent biotechnology company.
Keep Reading →
June 18 - News
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Keep Reading →
June 17 - Stock Analysis
According to the World Health Organization, there are 34 million HIV-positive individuals in the world today, and the virus has claimed the lives of 25 million people since the...
Keep Reading →
June 17 - News
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
June 13 - News
Our job here is to examine companies through an investing perspective.
Keep Reading →
June 12 - News
